

## Financial Tear Sheet

Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials. The company's lead candidate – an immunotherapy regimen combining our proprietary CRS-207 with GVAX Pancreas – is targeting metastatic pancreatic cancer and has received Breakthrough Therapy designation from the US Food and Drug Administration.

## Stock Quote

### ADRO (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$2.71**

Change (%) **+0.01 (0.37%)**


Volume 458,995

Data as of January 22, 2019 4:00 p.m. ET

Minimum 20 minute delay

[Refresh quote](#)

## Stock Chart



## Press Releases

January 03, 2019

[Aduro Biotech to Present at the 37th Annual J.P. Morgan Healthcare Conference](#)

December 18, 2018

[Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies](#)

## Events & Presentations

There are currently no events scheduled.

Data Provided by Thomson Reuters